Latest Insider Transactions at Maravai Lifesciences Holdings, Inc. (MRVI)
This section provides a real-time view of insider transactions for Maravai Lifesciences Holdings, Inc. (MRVI). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of MARAVAI LIFESCIENCES HOLDINGS, INC. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of MARAVAI LIFESCIENCES HOLDINGS, INC.'s insiders and make more informed investment decisions.
Insider Transaction List
Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
---|---|---|---|---|---|
Nov 15
2024
|
Rebecca Buzzeo Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
4,363
-1.2%
|
$17,452
$4.42 P/Share
|
Nov 12
2024
|
John A De Ford Director |
BUY
Open market or private purchase
|
Direct |
17,500
+19.99%
|
$87,500
$5.75 P/Share
|
Nov 11
2024
|
Carl Hull Director |
BUY
Open market or private purchase
|
Indirect |
175,000
+50.0%
|
$875,000
$5.64 P/Share
|
Oct 31
2024
|
Kevin Herde Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
1,906
+0.56%
|
$9,530
$5.7 P/Share
|
Oct 31
2024
|
Christine Dolan Officer |
BUY
Grant, award, or other acquisition
|
Direct |
1,848
+0.7%
|
$9,240
$5.7 P/Share
|
Oct 31
2024
|
Kurt Oreshack General Counsel |
BUY
Grant, award, or other acquisition
|
Direct |
366
+0.16%
|
$1,830
$5.7 P/Share
|
Oct 31
2024
|
Andrew Burch Officer |
BUY
Grant, award, or other acquisition
|
Direct |
1,841
+0.43%
|
$9,205
$5.7 P/Share
|
Oct 15
2024
|
William E. Martin Iii Chief Executive Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
50,843
-4.89%
|
$406,744
$8.29 P/Share
|
Jul 15
2024
|
Peter Michael Leddy Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
5,154
-1.35%
|
$41,232
$8.76 P/Share
|
May 28
2024
|
Gtcr Investment Xi LLC |
SELL
Open market or private sale
|
Indirect |
9,940,974
-33.04%
|
$89,468,766
$9.81 P/Share
|
May 28
2024
|
Gtcr Investment Xi LLC |
BUY
Conversion of derivative security
|
Indirect |
8,409,946
+21.84%
|
-
|
May 28
2024
|
Gtcr Investment Xi LLC |
SELL
Sale (or disposition) back to the issuer
|
Indirect |
8,409,946
-7.06%
|
-
|
May 23
2024
|
Gregory T Lucier Director |
BUY
Grant, award, or other acquisition
|
Direct |
20,645
+21.41%
|
$206,450
$10.78 P/Share
|
May 23
2024
|
Susannah Gray Director |
BUY
Grant, award, or other acquisition
|
Direct |
20,645
+20.36%
|
$206,450
$10.78 P/Share
|
May 23
2024
|
John A De Ford Director |
BUY
Grant, award, or other acquisition
|
Direct |
20,645
+28.21%
|
$206,450
$10.78 P/Share
|
May 23
2024
|
Luke Joseph Marker Director |
BUY
Grant, award, or other acquisition
|
Direct |
20,645
+29.68%
|
$206,450
$10.78 P/Share
|
May 23
2024
|
Jessica Hopfield Director |
BUY
Grant, award, or other acquisition
|
Direct |
20,645
+15.71%
|
$206,450
$10.78 P/Share
|
May 23
2024
|
Benjamin James Daverman Director |
BUY
Grant, award, or other acquisition
|
Direct |
20,645
+29.68%
|
$206,450
$10.78 P/Share
|
May 23
2024
|
Anat Ashkenazi Director |
BUY
Grant, award, or other acquisition
|
Direct |
20,645
+25.36%
|
$206,450
$10.78 P/Share
|
May 23
2024
|
Murali Prahalad Director |
BUY
Grant, award, or other acquisition
|
Direct |
20,645
+23.97%
|
$206,450
$10.78 P/Share
|
May 23
2024
|
Sean Laurence Cunningham Director |
BUY
Grant, award, or other acquisition
|
Direct |
20,645
+29.68%
|
$206,450
$10.78 P/Share
|
May 23
2024
|
Constantine S Mihas Director |
BUY
Grant, award, or other acquisition
|
Direct |
20,645
+29.68%
|
$206,450
$10.78 P/Share
|
Apr 30
2024
|
Peter Michael Leddy Officer |
BUY
Grant, award, or other acquisition
|
Direct |
4,576
+1.19%
|
$22,880
$5.7 P/Share
|
Apr 30
2024
|
Christine Dolan Officer |
BUY
Grant, award, or other acquisition
|
Direct |
483
+0.19%
|
$2,415
$5.7 P/Share
|
Apr 30
2024
|
Andrew Burch Officer |
BUY
Grant, award, or other acquisition
|
Direct |
1,719
+0.41%
|
$8,595
$5.7 P/Share
|
Apr 30
2024
|
Kevin Herde Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
1,780
+0.53%
|
$8,900
$5.7 P/Share
|
Apr 30
2024
|
Kurt Oreshack General Counsel |
BUY
Grant, award, or other acquisition
|
Direct |
341
+0.15%
|
$1,705
$5.7 P/Share
|
Apr 15
2024
|
Andrew Burch Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
16,758
-3.84%
|
$134,064
$8.11 P/Share
|
Mar 15
2024
|
Kurt Oreshack General Counsel |
SELL
Payment of exercise price or tax liability
|
Direct |
4,551
-2.0%
|
$31,857
$7.7 P/Share
|
Mar 15
2024
|
Rebecca Buzzeo Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
4,366
-1.18%
|
$30,562
$7.7 P/Share
|
Mar 15
2024
|
Kevin Herde Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
8,624
-2.53%
|
$60,368
$7.7 P/Share
|
Mar 15
2024
|
Peter Michael Leddy Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
6,714
-1.75%
|
$46,998
$7.7 P/Share
|
Mar 15
2024
|
Christine Dolan Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
5,383
-2.04%
|
$37,681
$7.7 P/Share
|
Mar 15
2024
|
Carl Hull Director |
SELL
Payment of exercise price or tax liability
|
Direct |
17,560
-6.17%
|
$122,920
$7.7 P/Share
|
Feb 15
2024
|
Carl Hull Director |
SELL
Payment of exercise price or tax liability
|
Direct |
10,729
-3.63%
|
$53,645
$5.48 P/Share
|
Feb 15
2024
|
Christine Dolan Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,941
-0.73%
|
$9,705
$5.48 P/Share
|
Feb 15
2024
|
Kevin Herde Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
2,664
-0.77%
|
$13,320
$5.48 P/Share
|
Feb 15
2024
|
Kurt Oreshack General Counsel |
SELL
Payment of exercise price or tax liability
|
Direct |
2,322
-1.01%
|
$11,610
$5.48 P/Share
|
Jan 16
2024
|
William E. Martin Iii Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
758,415
+42.16%
|
-
|
Jan 16
2024
|
Andrew Burch Officer |
BUY
Grant, award, or other acquisition
|
Direct |
295,782
+40.38%
|
-
|
Jan 16
2024
|
Kevin Herde Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
250,277
+42.1%
|
-
|
Jan 16
2024
|
Kurt Oreshack General Counsel |
BUY
Grant, award, or other acquisition
|
Direct |
166,852
+42.02%
|
-
|
Jan 16
2024
|
Peter Michael Leddy Officer |
BUY
Grant, award, or other acquisition
|
Direct |
250,277
+39.52%
|
-
|
Jan 16
2024
|
Rebecca Buzzeo Officer |
BUY
Grant, award, or other acquisition
|
Direct |
288,198
+43.82%
|
-
|
Jan 16
2024
|
Christine Dolan Officer |
BUY
Grant, award, or other acquisition
|
Direct |
189,604
+41.68%
|
-
|
Jan 16
2024
|
Carl Hull Director |
BUY
Grant, award, or other acquisition
|
Direct |
75,842
+20.43%
|
-
|
Nov 15
2023
|
Rebecca Buzzeo Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
4,549
-5.3%
|
$22,745
$5.19 P/Share
|
Oct 31
2023
|
Christine Dolan Officer |
BUY
Grant, award, or other acquisition
|
Direct |
1,729
+2.23%
|
$8,645
$5.83 P/Share
|
Oct 31
2023
|
Kevin Herde Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
1,861
+1.94%
|
$9,305
$5.83 P/Share
|
Oct 31
2023
|
Peter Michael Leddy Officer |
BUY
Grant, award, or other acquisition
|
Direct |
449
+0.34%
|
$2,245
$5.83 P/Share
|